Floodgates Open for US Humira Biosimilars; Key TB Drug Can Move in India

This month, the second wave of biosimilar Humira (adalimumab) sponsors ― as many as eight ― become free to launch their products. July also brings an end to Hikma’s six-month monopoly on generic competition to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution in the US. Read on for additional generics highlights.